ARTICLE SUMMARY:
Device companies seeking global market access can no longer ignore health technology assessment bodies, but there are an expanding number of HTA pathways that firms can utilize, particularly for truly innovative, next-generation technology, experts said during a recent panel discussion at MedTech Strategist’s Virtual Innovation Summit Dublin 2021. Check out the full video.
Global health technology assessment (HTA) agencies are an increasingly crucial audience for device companies hatching a global market access strategy. That was the message of a panel discussion centering on health technology assessment in the EU/UK at MedTech Strategist’s Virtual Innovation Summit Dublin 2021.
“There has been a tremendous change to how innovative technologies are adopted, and then diffused overtime, and these HTA bodies are playing an incredible role in saying what evidence is needed,” said Amit Kukreja, VP of Corporate Market Access & Reimbursement at Masimo.
Kukreja, who also discussed his HTA/market access experience for a first-in-class retinal prosthesis during his time at start-up Second Sight Medical Products, joined Paul Dimmock, an HTA adviser at the UK National Institute of Health and Care Excellence (NICE) and Michael Branagan-Harris, CEO of Device Access UK in a panel moderated by Market Pathways’ editor David Filmore.
Subscribers can watch the video below:
